You are here

  • Home
  • Archive
  • Volume 13, Issue Suppl 2
  • Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

Article info

Article menu
Download PDFPDF
Original Articles
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

Authors

  1. Address correspondence and reprint requests to: Martine J. Piccart, MD, Jules Bordet Institute, Chemotherapy Unit, Rue Heger-Bordet, 1, 1000 Brussels, Belgium. Email: martine.piccart{at}bordet.be

Citation

Piccart MJ, Bertelsen K, Stuart G, et al
Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer
International Journal of Gynecologic Cancer 2003;13:144-148.

Publication history

  • First published October 1, 2003.
Online issue publication 
March 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2003 Blackwell Science Ltd.